Drug Profile
ETBX 071
Alternative Names: Ad5 PSA; Adenoviral PSA vaccine - Etubics; ETBX071; PSA targeted vaccine - EtubicsLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Etubics Corporation
- Developer National Cancer Institute (USA)
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Metastatic disease) in USA (SC)
- 09 Mar 2021 National Cancer Institute completes a phase I trial in Prostate cancer (Metastatic disease; Combination therapy) in USA (SC) (NCT03481816)
- 05 Apr 2018 Phase-I clinical trials in Prostate cancer (Metastatic disease; Combination therapy) in USA (SC) (NCT03481816)